Extra-adrenal expression of Cyp21a1 for gene therapy of congenital adrenal hyperplasia

Cyp21a1 的肾上腺外表达用于先天性肾上腺增生症的基因治疗

基本信息

项目摘要

21-hydorxylase deficient (Cyp21a1D) mice were made by breeding with heterozygous of H-2aw18 haplotype mice. Retrovirus vector containing mouse Cyp21a1 cDNA was constructed and transmitted to fibroblasts cultured from 21OHD mice. Cyp21a1-induced fibroblasts were injected into Cyp21a1D mice. Adenoassociated virus vector containing Cyp21a cDNA (AAV-Cyp21a1) was constructed with pAAV-CMV-shuttle and injected into limbs muscles of 21OHD mice. Serum P4 and DOC concentrations were also measured before and after injection. Transplantation of the transgenic fibroblasts into Cyp21a1D mice showed slight change serum P4/DOC ratio. Transgenic 21OHD mice with AAV-Cyp21a1 showed increase DOC production and decreased P4/DOC ratio (1223 to 39.2) at 4weeks after injection. We succeeded recovering 21OH activity steroid production in in Cyp21a1D mice by introducing Cyp21a1 gene into muscle with adenoassociated virus vectors for 4 weeks.
21-羟化酶缺乏(CYP21A1D)小鼠是通过用H-2AW18单倍型小鼠的杂合繁殖而成的。构建了含有小鼠CYP21A1 cDNA的逆转录病毒载体,并将其传播到从21OHD小鼠中培养的成纤维细胞。将CYP21A1诱导的成纤维细胞注射到CYP21A1D小鼠中。用PAAV-CMV-Shuttle构建了含有CYP21A cDNA的腺体相关病毒载体(AAV-CYP21A1),并注入了21OHD小鼠的四肢肌肉中。还测量了在注射前后的血清P4和DOC浓度。将转基因成纤维细胞移植到CYP21A1D小鼠中显示出轻微的变化血清P4/DOC比。注射后4周,具有AAV-CYP21A1的转基因21OHD小鼠在4周时显示出DOC的产生增加,P4/DOC比(1223至39.2)降低。我们通过将CYP21A1基因引入肌肉中的肌肉中,在CYP21A1D小鼠中成功恢复了21OH活性类固醇的产生4周。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Novel intronic CYP21A2 mutation in Japanese patient with classic salt-wasting steroid 21-hydroxylase deficiency
日本典型耗盐类固醇 21-羟化酶缺乏症患者的新型内含子 CYP21A2 突变
  • DOI:
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    9.8
  • 作者:
    Nagamitsu S;et al;Noriyuki Katsumata
  • 通讯作者:
    Noriyuki Katsumata
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

NAIKI Yasuhiro其他文献

NAIKI Yasuhiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Development of AAV vector for in vivo treatment for congenital adrenal hyperplasia
用于体内治疗先天性肾上腺增生症的 AAV 载体的开发
  • 批准号:
    22K07950
  • 财政年份:
    2022
  • 资助金额:
    $ 2.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of gene therapy for congenital adrenal hyperplasia using AAV vectors and iPS cells
使用 AAV 载体和 iPS 细胞开发先天性肾上腺增生症基因治疗
  • 批准号:
    19K08359
  • 财政年份:
    2019
  • 资助金额:
    $ 2.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Comparison of pregnanetriol with blood 17-hydroxyprogesterone in 21-hydroxylase deficiency patients as the optimal control index
21-羟化酶缺乏症患者孕三醇与血17-羟孕酮作为最佳控制指标的比较
  • 批准号:
    19K18009
  • 财政年份:
    2019
  • 资助金额:
    $ 2.83万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of gene therapy for congenital adrenal hyperplasia using AAV vectors and iPS cells
使用 AAV 载体和 iPS 细胞开发先天性肾上腺增生症基因治疗
  • 批准号:
    16K10005
  • 财政年份:
    2016
  • 资助金额:
    $ 2.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Extra-Adrenal Induction of Cyp21a1 Ameliorates Systemic Steroid Metabolism in a Mouse Model of Congenital Adrenal Hyperplasia
Cyp21a1 的肾上腺外诱导可改善先天性肾上腺增生小鼠模型的全身类固醇代谢
  • 批准号:
    25461575
  • 财政年份:
    2013
  • 资助金额:
    $ 2.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了